On- and off-label use of rituximab in rheumatic diseases

Beyond Rheumatology 2021; 3 (1): e287
DOI: 10.4081/br.2021.56

The management of large vessel vasculitides

Beyond Rheumatology 2021; 3 (1): e286
DOI: 10.4081/br.2021.51

Recurrent ascites in systemic lupus erythematosus treated with rituximab – a case report and review of pseudo-pseudo Meigs’ syndrome

Beyond Rheumatology 2021; 3 (1): e285
DOI: 10.4081/br.2021.47

Asymptomatic versus symptomatic patients: [18F]FDG-PET/CT patterns and evolutionary track of COVID-19 associated vasculitis

Beyond Rheumatology 2021; 3 (1): e284
DOI: 10.4081/br.2021.45

Diffuse idiopathic skeletal hyperostosis: a review

Beyond Rheumatology 2021; 2 (3): e282
DOI: 10.4081/br.2020.52

Interstitial pneumonitis with autoimmune features: 2 case reports and review of literature

Beyond Rheumatology 2021; 2 (3): e280
DOI: 10.4081/br.2020.46

EULAR guidelines on ANCA-associated vasculitis in the real life

Beyond Rheumatology 2021; 2 (3): e281
DOI: 10.4081/br.2020.50

Paget bone disease demonstrated on 18F-fluorocholine PET/CT: a case report

Beyond Rheumatology 2020; 2 (3): e279
DOI: 10.4081/br.2020.44

When a rheumatologist encounters a Gardner-Diamond syndrome

Beyond Rheumatology 2020; 2 (3): e283
DOI: 10.4081/br.2020.53

Osteoporosis: prevention and personalized physiotherapy

Beyond Rheumatology 2020; 2 (3): e277
DOI: 10.4081/br.2020.36

• Newer
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• Older